LitAlert ~~

    • Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    • Kotani H, Masuda N, Yamashita T, Naito Y, Taira T, Inoue K, Takahashi M, Yonemori K, Toyoizumi S, Mori Y, Nagasawa T, Hori N, Iwata H.
    • Breast Cancer. 2022 Jul 30. doi: 10.1007/s12282-022-01390-w. Epub ahead of print.

    Identifier: NCT03343054: A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors. (

    • Motivational interviewing for genetic counseling: A unified framework for persuasive and equipoise conversations.
    • Resnicow K, Delacroix E, Chen G, Austin S, Stoffel E, Hanson EN, Gerido LH, Kaphingst KA, Yashar BM, Marvin M, Griggs JJ, Cragun D.
    • J Genet Couns. 2022 Jul 30. doi: 10.1002/jgc4.1609. Epub ahead of print.
    • Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC.
    • Ohsumi S, Nakamura S, Miyata H, Watanabe C, Den H, Arai M.
    • Jpn J Clin Oncol. 2022 Jul 30:hyac120. doi: 10.1093/jjco/hyac120. Epub ahead of print.
    • Fibroblast testing can inform medical management in individuals with mosaic variants detected on hereditary cancer panels.
    • Sutcliffe EG, Mester JL, Susswein LR, Roberts ME, Marshall ML, Hruska KS.
    • Cancer Genet. 2022 Jul 28. doi: 10.1016/j.cancergen.2022.07.004. Epub ahead of print.